4.7 Article

Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome Mouse Brain

Journal

MOLECULAR THERAPY
Volume 24, Issue 3, Pages 548-555

Publisher

CELL PRESS
DOI: 10.1038/mt.2015.236

Keywords

-

Funding

  1. NIH [NS071028]
  2. Angelman Syndrome Foundation
  3. Foundation for Angelman Syndrome Therapeutics
  4. NSF [0707429]
  5. Howard Hughes Medical Institute through the Med into Grad Initiative [56005706]
  6. CTSC pilot study [TR000002]
  7. CMGI pilot grant
  8. UC Davis Biotechnology Program
  9. NIH Molecular and Cellular Biology Training Program [GM007377]
  10. Direct For Education and Human Resources [0707429] Funding Source: National Science Foundation
  11. Division Of Graduate Education [0707429] Funding Source: National Science Foundation

Ask authors/readers for more resources

Angelman syndrome (AS) is a neurological genetic disorder caused by loss of expression of the maternal copy of UBE3A in the brain. Due to brain-specific genetic imprinting at this locus, the paternal UBE3A is silenced by a long antisense transcript. Inhibition of the antisense transcript could lead to unsilencing of paternal UBE3A, thus providing a therapeutic approach for AS. However, widespread delivery of gene regulators to the brain remains challenging. Here, we report an engineered zinc finger-based artificial transcription factor (ATF) that, when injected i.p. or s.c., crossed the blood brain barrier and increased Ube3a expression in the brain of an adult mouse model of AS. The factor displayed widespread distribution throughout the brain. Immunohistochemistry of both the hippocampus and cerebellum revealed an increase in Ube3a upon treatment. An ATF containing an alternative DNA binding domain did not activate Ube3a. We believe this to be the first report of an injectable engineered zinc finger protein that can cause widespread activation of an endogenous gene in the brain. These observations have important implications for the study and treatment of AS and other neurological disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available